Investors locked in profits on Arena Pharmaceuticals Inc. (Nasdaq: ARNA), whose stock price climbed the last two days after announcing that European regulators accepted the marketing application for its weight loss treatment Lorcaserin. Shares of the biopharmaceutical lost 34 cents to close at $2.92.
Profit Taking Sinks Arena
March 28, 2012 at 17:59 PM EDT
